Several studies exhibited equivalence in terms of plasma curcuminoids, which allows it to be considered a replacement against large doses of conventional turmeric extracts
Nutriventia's clinically studied turmeric ingredient TurmXTRA has been awarded patents in the US and the UK.
These patents have been a priority in the innovation pipeline at Nutriventia and apply to the curcuminoid formulations exhibiting rapid dissolution and optimising bioavailability from a low 250 mg once-a-day dose. TurmXTRA is also Clean Label Project certified, as it uses excipients obtained from natural sources and is derived from a solvent free manufacturing process.
TurmXTRA has recently been lauded for its optimised bioavailability and clinical efficacy at a low 250mg dosage. Several studies exhibited equivalence in terms of plasma curcuminoids, which allows it to be considered a replacement against large doses of conventional turmeric extracts and revealed benefits for TurmXTRA in Joint Health and Muscle Recovery. This significantly benefits consumers by providing efficacy from a convenient once-a-day low dose.
“We are very proud to receive the patents for TurmXTRA in our two leading markets, the US and the UK,” said Rajat Shah, co-founder and Executive Director of Nutriventia. “The curcumin product patent space is crowded with extract-composition formulas and their health applications; patents in this space also mainly cover the use of surfactants, oils or bioactive absorption enhancers,” she added.
With science-backed bioequivalence for curcuminoids delivery in plasma and a high 60% potency formulation, the company says it is "not surprised to see demonstrated efficacy at 250mg TurmXTRA."
